Meeting
2019 ASCO Annual Meeting
Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).
Authors
Anis Hamid
Dana-Farber Cancer Institute, Boston, MA
Anis Hamid , Himisha Beltran , Atish Dipankar Choudhury , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5018)
DOI
10.1200/JCO.2019.37.15_suppl.5018
Abstract #
5018
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).
First Author: Ryon Graf
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2018 Genitourinary Cancers Symposium
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).
First Author: Daniel Khalaf
Poster
2018 Genitourinary Cancers Symposium
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Charles J. Ryan